BRAF p.V600E is also detected in aggressive, high-grade tumors arising from the progression of conventional papillary carcinoma, with reported frequencies ranging from 10 to 50–60% for high-grade non-anaplastic carcinomas (HGDTC and PDTC) and from 10 to 50% for anaplastic carcinomas (Fig. 1 and Table 2) (6, 12, 19, 37, 38). This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.